

Adam Bisaga

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7858494/adam-bisaga-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

2,743
citations

32
h-index

50
g-index

80
ext. papers

3,066
ext. citations

5.5
avg, IF

5.14
L-index

#	Paper	IF	Citations
74	Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.. <i>Drug and Alcohol Dependence</i> , 2022 , 233, 109343	4.9	0
73	Delay discounting and neurocognitive correlates among inner city adolescents with and without family history of substance use disorder. <i>Developmental Cognitive Neuroscience</i> , 2021 , 48, 100942	5.5	3
72	Quetiapine treatment for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2021 , 218, 108366	4.9	4
71	Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. <i>Drug and Alcohol Dependence</i> , 2021 , 219, 108482	4.9	1
70	Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. <i>Psychopharmacology</i> , 2020 , 237, 2233-2255	4.7	32
69	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. <i>Drug and Alcohol Dependence</i> , 2020 , 206, 107700	4.9	21
68	A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2020 , 46, 289-296	3.7	5
67	Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , 2020 , 115, 2188-2190	4.6	
66	Medical Student Attitudes Toward Substance Use Disorders Before and After a Skills-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Curriculum. <i>Advances in Medical Education and Practice</i> , 2020 , 11, 455-461	1.5	6
65	Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , 2020 , 115, 239-246	4.6	10
64	What should clinicians do as fentanyl replaces heroin?. <i>Addiction</i> , 2019 , 114, 782-783	4.6	19
63	Development of a Cascade of Care for responding to the opioid epidemic. <i>American Journal of Drug and Alcohol Abuse</i> , 2019 , 45, 1-10	3.7	111
62	A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. <i>American Journal of Psychiatry</i> , 2019 , 176, 129-137	11.9	42
61	Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. <i>Drug and Alcohol Dependence</i> , 2018 , 187, 171-178	4.9	26
60	Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. <i>American Journal on Addictions</i> , 2018 , 27, 177-187	3.7	26
59	Developing an opioid use disorder treatment cascade: A review of quality measures. <i>Journal of Substance Abuse Treatment</i> , 2018 , 91, 57-68	4.2	79
58	Contingency Management with pharmacologic treatment for Stimulant Use Disorders: A review. <i>Behaviour Research and Therapy</i> , 2018 , 111, 57-63	5.2	11

57	The PPAR α Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. <i>Journal of Psychoactive Drugs</i> , 2018 , 50, 390-401	3.6	12
56	Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. <i>American Journal of Psychiatry</i> , 2017 , 174, 459-467	4.9	60
55	Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders. <i>American Journal on Addictions</i> , 2017 , 26, 319-325	3.7	14
54	Pioglitazone, a PPAR α agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. <i>Pharmacology Biochemistry and Behavior</i> , 2017 , 163, 90-100	3.9	21
53	From AIDS to Opioids - How to Combat an Epidemic. <i>New England Journal of Medicine</i> , 2016 , 375, 813-5	59.2	55
52	Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. <i>Drug and Alcohol Dependence</i> , 2016 , 159, 53-60	4.9	56
51	A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. <i>American Journal on Addictions</i> , 2016 , 25, 603-609	3.7	32
50	Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers. <i>Journal of Psychopharmacology</i> , 2016 , 30, 370-7	4.6	3
49	Ling et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. <i>Addiction</i> , 2015 , 110, 875-6	4.6	2
48	Baseline characteristics of patients predicting suitability for rapid naltrexone induction. <i>American Journal on Addictions</i> , 2015 , 24, 258-264	3.7	11
47	The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. <i>Drug and Alcohol Dependence</i> , 2015 , 154, 38-45	4.9	57
46	Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. <i>Drug and Alcohol Dependence</i> , 2015 , 147, 122-9	4.9	20
45	Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?. <i>Drug and Alcohol Dependence</i> , 2014 , 144, 42-6	4.9	12
44	A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. <i>Journal of Substance Abuse Treatment</i> , 2014 , 46, 546-52	4.2	30
43	A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. <i>American Journal on Addictions</i> , 2014 , 23, 68-75	3.7	21
42	Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?. <i>Drug and Alcohol Dependence</i> , 2013 , 133, 80-5	4.9	32
41	Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement. <i>Drug and Alcohol Dependence</i> , 2013 , 128, 77-82	4.9	27
40	A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. <i>Addiction</i> , 2013 , 108, 1084-94	4.6	60

39	Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. <i>Biological Psychiatry</i> , 2012 , 72, 950-6	7.9	59
38	Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. <i>American Journal of Drug and Alcohol Abuse</i> , 2012 , 38, 187-99	3.7	78
37	Comparison of substance use milestones in cannabis- and cocaine-dependent patients. <i>Journal of Addictive Diseases</i> , 2012 , 31, 60-6	1.7	7
36	A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2011 , 119, e23-9	4.9	30
35	Comparison of clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants. <i>Journal of Substance Abuse Treatment</i> , 2011 , 40, 426-30	4.2	8
34	A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. <i>American Journal on Addictions</i> , 2011 , 20, 441-6	3.7	21
33	Memantine reduces consumption of highly palatable food in a rat model of binge eating. <i>Amino Acids</i> , 2011 , 40, 477-85	3.5	30
32	A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. <i>Drug and Alcohol Dependence</i> , 2010 , 111, 97-104	4.9	42
31	Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1371-8	4.6	24
30	Acute interaction of baclofen in combination with alcohol in heavy social drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2009 , 33, 19-30	3.7	68
29	Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. <i>American Journal on Addictions</i> , 2009 , 18, 301-8	3.7	45
28	Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial. <i>Journal of Dual Diagnosis</i> , 2009 , 5, 41-56	2.4	35
27	Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. <i>Psychology of Addictive Behaviors</i> , 2009 , 23, 47-55	3.4	13
26	Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice. <i>Drug and Alcohol Dependence</i> , 2008 , 95, 147-51	4.9	9
25	Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. <i>European Neuropsychopharmacology</i> , 2008 , 18, 794-802	1.2	43
24	Antisocial behavioral syndromes in cocaine and cannabis dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2008 , 34, 405-14	3.7	18
23	Cognition, commitment language, and behavioral change among cocaine-dependent patients. <i>Psychology of Addictive Behaviors</i> , 2008 , 22, 557-62	3.4	88
22	A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine. <i>Psychopharmacology</i> , 2008 , 199, 583-92	4.7	10

21	Effects of alternative reinforcer and craving on the choice to smoke cigarettes in the laboratory. <i>Human Psychopharmacology</i> , 2007 , 22, 41-7	2.3	12
20	Early abstinence in cocaine dependence: influence of comorbid major depression. <i>American Journal on Addictions</i> , 2007 , 16, 283-90	3.7	15
19	Insula damage and quitting smoking. <i>Science</i> , 2007 , 317, 318-9; author reply 318-9	33.3	10
18	Management of relapse in naltrexone maintenance for heroin dependence. <i>Drug and Alcohol Dependence</i> , 2007 , 91, 289-92	4.9	45
17	Severity of dependence and motivation for treatment: comparison of marijuana- and cocaine-dependent treatment seekers. <i>Journal of Addictive Diseases</i> , 2006 , 25, 33-41	1.7	14
16	A randomized placebo-controlled trial of gabapentin for cocaine dependence. <i>Drug and Alcohol Dependence</i> , 2006 , 81, 267-74	4.9	65
15	Cognitive deficits predict low treatment retention in cocaine dependent patients. <i>Drug and Alcohol Dependence</i> , 2006 , 81, 313-22	4.9	314
14	The acute effects of gabapentin in combination with alcohol in heavy drinkers. <i>Drug and Alcohol Dependence</i> , 2006 , 83, 25-32	4.9	36
13	Reinstatement of morphine-conditioned reward is blocked by memantine. <i>Neuropsychopharmacology</i> , 2006 , 31, 160-70	8.7	58
12	Glutamatergic Agents for Nicotine Dependence 2006 , 167-176		
11	Utility of lead-in period in cocaine dependence pharmacotherapy trials. <i>Drug and Alcohol Dependence</i> , 2005 , 77, 7-11	4.9	23
10	Comparison of serum fatty acid ethyl esters and urinary 5-hydroxytryptophol as biochemical markers of recent ethanol consumption. <i>Alcohol and Alcoholism</i> , 2005 , 40, 214-8	3.5	17
9	Acute effects of memantine in combination with alcohol in moderate drinkers. <i>Psychopharmacology</i> , 2004 , 172, 16-24	4.7	69
8	Interaction between naltrexone and oral THC in heavy marijuana smokers. <i>Psychopharmacology</i> , 2003 , 166, 77-85	4.7	67
7	The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. <i>Psychopharmacology</i> , 2001 , 157, 1-10	4.7	101
6	In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. <i>Drug and Alcohol Dependence</i> , 2000 , 59, 1-15	4.9	82
5	Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 2233-48	5.9	34
4	Cerebral glucose metabolism in women with panic disorder. <i>American Journal of Psychiatry</i> , 1998 , 155, 1178-83	11.9	112

3	Effect of glutamate receptor antagonists on N-methyl-D-aspartate- and (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced convulsant effects in mice and rats. <i>European Journal of Pharmacology</i> , 1993 , 242, 213-20	5.3	40
2	Individual behavioral differences and ethanol consumption in Wistar rats. <i>Physiology and Behavior</i> , 1993 , 54, 1125-31	3.5	40
1	Recognition cue in the rat's social memory paradigm. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 1991 , 2, 315-27	1.6	36